Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13cyclopia sequence 7Neoplasms 6Multiple Myeloma 6Fatigue 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 4Lung Neoplasms 4Dyspnea 4Carcinoma, Non-Small-Cell Lung 4Anxiety Disorders 4Uterine Cervical Neoplasms 3Tobacco Use Cessation 3Prostatic Neoplasms 3Primary Myelofibrosis 3Leukemia 3Head and Neck Neoplasms 3Depression 3Carcinoma, Renal Cell 3Vomiting 2Smoking Cessation 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Parasomnias 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2

Interventions

Celecoxib 4Sulindac 2Erlotinib Hydrochloride 2Eflornithine 2Curcumin 2Surveys and Questionnaires 1Suppositories 1Sirolimus 1Sigmoidoscopy 1Gastroscopy 1Endoscopy 1Eicosapentaenoic Acid 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenomatous Polyposis Coli × Surveys and Questionnaires × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡